Related references
Note: Only part of the references are listed.Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer
Loujin Houdaihed et al.
MOLECULAR PHARMACEUTICS (2018)
Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus
Enrica Chiesa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
Serena Mazzucchelli et al.
ONCOTARGET (2017)
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model
Verena Damiani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents
Emanuela Cova et al.
NANOTOXICOLOGY (2017)
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
S. Mazzucchelli et al.
SCIENTIFIC REPORTS (2017)
H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells
Laura Pandolfi et al.
BIOMACROMOLECULES (2017)
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanovic et al.
CLINICAL CANCER RESEARCH (2017)
Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer
Marta Truffi et al.
PHARMACOLOGICAL RESEARCH (2016)
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Sara A. Hurvitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction
Emanuela Cova et al.
NANOMEDICINE (2015)
Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells
Michela Bellini et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection
Minmin Liang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors
Zipeng Zhen et al.
ACS NANO (2013)
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
Hsiao-Ching Chuang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Magnetoferritin nanoparticles for targeting and visualizing tumour tissues
Kelong Fan et al.
NATURE NANOTECHNOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1
Li Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
Babette Schade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
Protein-Based Nanomedicine Platforms for Drug Delivery
Aihui MaHam et al.
SMALL (2009)
Pharmacokinetics and biodistribution of nanoparticles
Shyh-Dar Li et al.
MOLECULAR PHARMACEUTICS (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
GJ Wu et al.
BREAST CANCER RESEARCH (2005)
Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells
LM Mooney et al.
BRITISH JOURNAL OF CANCER (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Share Paper
